Suppliers / Symbio Pharmaceuticals

Symbio Pharmaceuticals

Japan 39 employees Updated 9 July 2026

Symbio Pharmaceuticals is an API manufacturer based in Japan. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with CDSCO (India) and EMA.

2
active US DMFs
0
valid CEPs
0
registered plants
4
filings across 2 regulators

What they file, and where

Molecule Regulators Docs
Minoxidil US FDA 1
Ursodeoxycholic Acid US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 3 None
EMA 1 None

Questions about Symbio Pharmaceuticals

Does Symbio Pharmaceuticals hold a US DMF or a CEP?
Symbio Pharmaceuticals holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Symbio Pharmaceuticals make?
2 molecules are on record against Symbio Pharmaceuticals, including Minoxidil and Ursodeoxycholic Acid. Each links through to that molecule's full manufacturer list.
Where does Symbio Pharmaceuticals file?
Filings are on record with CDSCO (India) and EMA, 4 in total.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Symbio Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability